Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 8-K (Current Report)
Report Date: March 19, 2026
Reporting Period: Year ended December 31, 2025
Context: The Company issued a press release announcing its financial results for the full year 2025. The press release is included as Exhibit 99.1 to this filing.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing the press release (Exhibit 99.1) but does not contain specific numerical data. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the issuance of a press release regarding 2025 results but does not include the text of the commentary, guidance, or outlook.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided 8-K text.
Unusual Items: No unusual items are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for the year ended December 31, 2025.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial milestones or partnership agreements mentioned in the press release.
- Confirm if the Company provided updated financial guidance for 2026 in the press release.